Literature DB >> 12730502

Cytokine balance in kidney tissue from lupus nephritis patients.

W-S Uhm1, K Na, G-W Song, S-S Jung, T Lee, M-H Park, D-H Yoo.   

Abstract

OBJECTIVE: To identify the balance of Th1/Th2 cytokine expression in the kidney and evaluate the difference in cytokine balance between patients with lupus nephritis WHO classes IV and V.
METHODS: The expression of the CD40 molecule on cultured human mesangial cells was assessed by flow cytometry after stimulation with interferon gamma (IFN-gamma) or other cytokines. Frozen sections of kidney tissue from 10 patients with lupus nephritis and two non-SLE patients (with minimal-change disease) were stained with monoclonal antibodies for interleukin (IL)-4, IL-10, IL-12, IFN-gamma, CD4, CD8, CD40, CD68 and CD40L.
RESULTS: CD40 expression of cultured mesangial cells was up-regulated by IFN-gamma, but was not down-regulated in the presence of the Th2 cytokines IL-4 and IL-10. In the glomeruli, CD40 expression and the ratios of IFN-gamma-/IL-10-, IL-12-/IL-4- and (IFN-gamma+IL-12)/(IL-4+IL-10)-positive cells were significantly higher in class IV than in class V lupus nephritis (P < 0.05). Also CD40, IFN-gamma and the activity index derived from the renal biopsy were closely correlated.
CONCLUSION: IFN-gamma may contribute to the pathogenesis of proliferative glomerulonephritis by the up-regulation of CD40 and the activation of the cellular immune response in human lupus.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12730502     DOI: 10.1093/rheumatology/keg255

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  34 in total

Review 1.  Cytokines as therapeutic targets in SLE.

Authors:  Lars Rönnblom; Keith B Elkon
Journal:  Nat Rev Rheumatol       Date:  2010-05-04       Impact factor: 20.543

Review 2.  Lupus nephritis: the evolving role of novel therapeutics.

Authors:  Brad H Rovin; Samir V Parikh
Journal:  Am J Kidney Dis       Date:  2014-01-07       Impact factor: 8.860

3.  Novel treatments for systemic lupus erythematosus.

Authors:  Wen Xiong; Robert G Lahita
Journal:  Ther Adv Musculoskelet Dis       Date:  2011-10       Impact factor: 5.346

4.  Elevated interleukin-18 and skewed Th1:Th2 immune response in lupus nephritis.

Authors:  Xiaoqian Liu; Chunde Bao; Dawei Hu
Journal:  Rheumatol Int       Date:  2010-10-21       Impact factor: 2.631

Review 5.  Cytokine networks in systemic lupus erythematosus.

Authors:  Hooi-Ming Lee; Hidehiko Sugino; Norihiro Nishimoto
Journal:  J Biomed Biotechnol       Date:  2010-04-15

Review 6.  Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances.

Authors:  Desmond Yat Hin Yap; Kar Neng Lai
Journal:  J Biomed Biotechnol       Date:  2010-05-06

Review 7.  Role of interleukin-10 and interleukin-10 receptor in systemic lupus erythematosus.

Authors:  Hui Peng; Wei Wang; Mo Zhou; Rui Li; Hai-Feng Pan; Dong-Qing Ye
Journal:  Clin Rheumatol       Date:  2013-05-25       Impact factor: 2.980

8.  CTGF promotes inflammatory cell infiltration of the renal interstitium by activating NF-kappaB.

Authors:  Elsa Sánchez-López; Sandra Rayego; Raquel Rodrigues-Díez; Javier Sánchez Rodriguez; Raúl Rodrigues-Díez; Juan Rodríguez-Vita; Gisselle Carvajal; Luiz Stark Aroeira; Rafael Selgas; Sergio A Mezzano; Alberto Ortiz; Jesús Egido; Marta Ruiz-Ortega
Journal:  J Am Soc Nephrol       Date:  2009-05-07       Impact factor: 10.121

9.  Up-regulation of IL-18 and predominance of a Th1 immune response is a hallmark of lupus nephritis.

Authors:  N Calvani; H B Richards; M Tucci; G Pannarale; F Silvestris
Journal:  Clin Exp Immunol       Date:  2004-10       Impact factor: 4.330

10.  Overexpression of interleukin-12 and T helper 1 predominance in lupus nephritis.

Authors:  M Tucci; L Lombardi; H B Richards; F Dammacco; F Silvestris
Journal:  Clin Exp Immunol       Date:  2008-09-15       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.